×
About 590 results

ALLMedicine™ Prurigo Nodularis Center

Research & Reviews  172 results

Efficacy of Abrocitinib for Reducing Pruritus in Adults With Prurigo Nodularis and Chronic Pruritus of Unknown Origin
https://clinicaltrials.gov/ct2/show/NCT05038982

Jul 27th, 2022 - This is a trial to assess the efficacy of Abrocitinib as a therapeutic for Prurigo Nodularis (PN) and Chronic Pruritus of Unknown Origin (CPUO). The study will consist of a 4-week Screening period, a 12-week treatment period and then a 4-week foll...

A Study to Evaluate the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis
https://clinicaltrials.gov/ct2/show/NCT05061693

Jul 27th, 2022 - The purpose of this study is to evaluate the efficacy and safety of INCB054707 in participants with prurigo nodularis over a 16-week double-blind placebo-controlled treatment period, followed by a 24 -week single blind extension period.

Nemolizumab: First Approval.
https://doi.org/10.1007/s40265-022-01741-z
Drugs Keam SJ

Jul 15th, 2022 - Nemolizumab is a subcutaneously administered humanized anti-interleukin-31 (IL-31) receptor A (IL-31RA) monoclonal antibody that is being developed by Chugai Pharmaceutical Co. Ltd, Maruho Co. Ltd and Galderma Pharma S.A. for the treatment of skin...

A Study to Evaluate the Durability of Response and Safety of Nemolizumab for 24 Weeks in Participants With Prurigo Nodularis
https://clinicaltrials.gov/ct2/show/NCT05052983

Jul 13th, 2022 - The primary objective of this study is to assess the long-term durability of response over a 24-week period following withdrawal of nemolizumab in participants with prurigo nodularis (PN) who previously responded to treatment in the Long-term-Exte...

A Study to Assess Change in Disease Activity in Adolescents and Adults With Moderate to Severe Prurigo-type Atopic Dermatitis in Japan Who Are Treated With Oral Upadacitinib
https://clinicaltrials.gov/ct2/show/NCT05451316

Jul 11th, 2022 - Atopic dermatitis (AD) is a skin condition that may cause a rash and itching due to inflammation of the skin. Around one-third of patients with AD have had at least 1 incidence of prurigo nodularis (PN), which is characterized by intense, persiste...

see more →

Clinicaltrials.gov  23 results

Efficacy of Abrocitinib for Reducing Pruritus in Adults With Prurigo Nodularis and Chronic Pruritus of Unknown Origin
https://clinicaltrials.gov/ct2/show/NCT05038982

Jul 27th, 2022 - This is a trial to assess the efficacy of Abrocitinib as a therapeutic for Prurigo Nodularis (PN) and Chronic Pruritus of Unknown Origin (CPUO). The study will consist of a 4-week Screening period, a 12-week treatment period and then a 4-week foll...

A Study to Evaluate the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis
https://clinicaltrials.gov/ct2/show/NCT05061693

Jul 27th, 2022 - The purpose of this study is to evaluate the efficacy and safety of INCB054707 in participants with prurigo nodularis over a 16-week double-blind placebo-controlled treatment period, followed by a 24 -week single blind extension period.

A Study to Evaluate the Durability of Response and Safety of Nemolizumab for 24 Weeks in Participants With Prurigo Nodularis
https://clinicaltrials.gov/ct2/show/NCT05052983

Jul 13th, 2022 - The primary objective of this study is to assess the long-term durability of response over a 24-week period following withdrawal of nemolizumab in participants with prurigo nodularis (PN) who previously responded to treatment in the Long-term-Exte...

A Study to Assess Change in Disease Activity in Adolescents and Adults With Moderate to Severe Prurigo-type Atopic Dermatitis in Japan Who Are Treated With Oral Upadacitinib
https://clinicaltrials.gov/ct2/show/NCT05451316

Jul 11th, 2022 - Atopic dermatitis (AD) is a skin condition that may cause a rash and itching due to inflammation of the skin. Around one-third of patients with AD have had at least 1 incidence of prurigo nodularis (PN), which is characterized by intense, persiste...

An Efficacy and Safety Study of Nemolizumab (CD14152) in Participants With Prurigo Nodularis
https://clinicaltrials.gov/ct2/show/NCT04501666

Jun 30th, 2022 - The primary objective is to assess the efficacy of nemolizumab (CD14152) compared to placebo in participants greater than or equal to (>=) 18 years of age with prurigo nodularis (PN) after a 16 week treatment period.

see more →

News  41 results

Dupilumab Treats Itch and Clears Lesions in Prurigo Nodularis Patients
https://www.medscape.com/viewarticle/971314

Mar 31st, 2022 - BOSTON ― Dupilumab, a human monoclonal IgG4 antibody, was an effective treatment for prurigo nodularis (PN), improving itching and skin lesions after 12 and 24 weeks of treatment, in a phase 3 trial presented at the American Academy of Dermatology...

Pruritic Eruption on the Trunk and Extremities
https://www.mdedge.com/dermatology/article/250201/dermatopathology/pruritic-eruption-trunk-and-extremities
David Micah Milgraum, MD, Alexandra Rubin, MBS et. al.

Dec 23rd, 2021 - THE DIAGNOSIS: Acquired Perforating Disorder of Renal Disease A papule with the central plug removed left a pitlike depression, representing Kyrle disease (Figure 1). A punch biopsy of the left forearm revealed epidermal hyperplasia (Figure 2A) su.

Prurigo nodularis has two disease endotypes, a cluster analysis shows
https://www.mdedge.com/dermatology/article/250075/medical-dermatology/prurigo-nodularis-has-two-disease-endotypes-cluster
Christine Kilgore

Dec 20th, 2021 - A cluster analysis of circulating plasma biomarkers in prurigo nodularis (PN) has identified two disease endotypes with inflammatory and noninflammatory biomarker profiles. Dr.

Common Outcome Measures for AD Lack Adequate Reporting of Race, Skin Tone
https://www.medscape.com/viewarticle/955588

Jul 28th, 2021 - Many validation studies of clinician- and patient-reported outcome measures for atopic dermatitis (AD) lack adequate reporting of race, ethnicity, and skin tone, according to results from a systematic review. Trisha Kaundinya "AD is associated wit...

Common outcome measures for AD lack adequate reporting of race, skin tone
https://www.mdedge.com/dermatology/article/243462/atopic-dermatitis/common-outcome-measures-ad-lack-adequate-reporting-race
Doug Brunk

Jul 27th, 2021 - Many validation studies of clinician- and patient-reported outcome measures for atopic dermatitis (AD) lack adequate reporting of race, ethnicity, and skin tone, according to results from a systematic review. Trisha Kaundinya “AD is associated wit.

see more →